What is DVT, a non-surgical treatment for severe pain that is popular with some doctors, and has been used in many studies to treat chronic pain, has also been popular among patients with other chronic conditions, and may be used as a treatment option for other conditions.
A review published in the Annals of Internal Medicine on July 1 found that patients who received DVT therapy showed a significant decrease in the number of severe pain episodes compared with those who received standard medical care.
The study was led by Dr. Steven E. Stahl, director of the Center for the Study of Chronic Pain at Harvard Medical School.
The researchers also analyzed data from more than 20,000 patients with chronic pain who received either standard or DVT for a year.
The authors reported that patients treated with DVT had a significant reduction in the severity of their pain compared with patients who did not receive DVT.
The reduction in pain severity was more than 50 percent.
The number of patients with pain that was so severe that it required emergency room care decreased from 17.5 percent in patients treated without DVT to 0.7 percent in those who were treated with the drug.
The DVT group also had significantly lower rates of pain-related hospitalizations, which is a condition known as acute myocardial infarction (AMI), the researchers said.
The results may help explain why some doctors are recommending that patients with DPT use DVT as a way to manage chronic pain.
“We know that this treatment reduces pain, so that’s important, but it may be that the pain relief comes with other benefits,” Dr. Stahn said.
For example, the DPT group may reduce inflammation and increase the activity of some parts of the body, the researchers added.
DVT may also have therapeutic value in the management of some other chronic pain conditions, including multiple sclerosis (MS), rheumatoid arthritis, multiple sclerosis, and chronic pain syndrome.
The treatment, which requires patients to wear a mask for at least three days, is commonly used in MS to manage pain, but the drug has not been approved for use in the treatment of MS.
Dr. Richard P. Katz, the president of the American College of Rheumatology, said in a statement that the study was significant because it provides a basis for further investigation of DPT.
“The clinical benefit of DVT is well-established and has significant promise,” he said.
“But the evidence base is sparse.
As such, we recommend patients seek additional information before making any definitive conclusions.”
The authors said that they were not aware of any other study to demonstrate that DPT therapy reduces pain for people with chronic conditions other than MS.
However, Dr. Katz said that other research has indicated that DVT can reduce the severity and frequency of chronic pain for a wide variety of chronic conditions.
For instance, a 2016 study found that DCT may be helpful in reducing pain for patients with multiple sclerosis and for other patients who have moderate to severe pain.
In a similar study, Drs.
John C. Soderberg and Matthew M. Schulte, of the University of California, Los Angeles, and David H. Schwartz, of Duke University Medical Center, reported that DTT may help manage chronic back pain in adults with chronic fatigue syndrome (CFS).
Dr. Schwartz is a professor of neurology at the University at Buffalo.
He and his colleagues enrolled more than 700 CFS patients in their ongoing study.
In their study, the team found that treatment with DTT reduced the severity, frequency and number of symptoms associated with CFS symptoms, such as fatigue, sleep disturbances, and poor concentration.
“While the study results are encouraging, it is important to note that the current data do not address the efficacy of DTT in the clinical setting for CFS,” Drs Soderburg and Schultecks said.
Drs Katz said it was important to know more about the efficacy and safety of DCT and to make sure that the drug is not prescribed inappropriately.
“I do not think this study is helpful in our clinical decision-making, but I would hope that we would get some kind of response from the FDA in that regard,” he added.
Dr Katz noted that other patients are using DPT as a primary treatment option to manage other conditions that can also result in chronic pain or disability, including migraines and chronic fatigue.
However of those who are taking DCT, about two-thirds said they would use the drug for chronic pain and about 20 percent said they had previously been treated for pain.
Dr Soderbergh, who was not involved in the study, said the findings could help explain the popularity of DTS among patients.
“DVT is being touted as a promising alternative to standard medical treatment for chronic conditions,” he wrote in an email.
“Although it may not be as safe or effective as standard medical treatments, it seems to have some potential to reduce pain in patients with a variety of other conditions.” The